Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic amp responsive element binding protein gene
Abstract
The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.
Claims
exact text as granted — not AI-modified1 . A method for evaluating drug sensitivity, comprising associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with an individual drug sensitivity.
2 . The method according to claim 1 , wherein a tendency in the presence or absence of an individual drug sensitivity is evaluated based on the results from the analysis of the gene polymorphism or the haplotype.
3 . The method according to claim 1 , comprising the following steps:
(1) a step of performing linkage disequilibrium analysis and haplotype analysis on a healthy subject and selecting gene polymorphisms in a linkage disequilibrium block; (2) a step of analyzing the association between the genotypes of the gene polymorphisms and drug sensitivity in a test subject; and (3) a step of using the gene polymorphism that has been significantly associated with drug sensitivity in the test subject for evaluation of the drug sensitivity.
4 . A method for evaluating disease vulnerability, comprising associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with an individual disease vulnerability.
5 . The method according to claim 4 , wherein a tendency in the presence or absence of an individual disease vulnerability is evaluated based on the results from the analysis of the gene polymorphism or the haplotype.
6 . The method according to claim 4 , comprising the following steps:
(1) a step of performing linkage disequilibrium analysis and haplotype analysis on a healthy subject and selecting gene polymorphisms in a linkage disequilibrium block; (2) a step of comparing the frequency of gene polymorphisms in a test subject with the frequency of gene polymorphisms in the healthy subject; and (3) a step of using the gene polymorphism that has a significant difference in the gene polymorphism frequency between the test subject and the healthy subject for evaluation of the disease vulnerability.
7 . The method according to claim 4 , wherein the disease vulnerability is pain sensitivity or vulnerability to substance dependence.
8 . The method according to claim 1 or 4 , wherein the gene polymorphism is at least one selected from the group consisting of a single nucleotide polymorphism, an insertion polymorphism, a deletion polymorphism, and a nucleotide repeat polymorphism.
9 . The method according to claim 1 or 4 , wherein the gene polymorphism is at least one selected from among: rs16839837, rs2360969, rs10932200, rs2253206, rs2551640, rs11904814, rs16839883, rs6740584, rs3770704, rs2254137, rs2551645, rs2551946, rs4234080, rs2952768, rs2709386, rs7591784, and rs7594560 of a CREB1 subtype gene; rs1243872, rs2145925, rs2025126, rs1885373, rs1885374, GA007473, rs2295794, rs4879926, GA007477, rs867194, rs11541908, rs741917, rs7862485, rs2756894, rs2249250, rs2295795, rs877365, rs2737273, rs2295797, rs2295798, rs1534847, rs7873822, rs2737274, rs10972567, rs3763630, rs10814274, rs3750434, rs1570246, GA025684, rs1570248, rs1570249, rs34478611, rs1322045, rs1951432, GA025687, rs10814275, rs10758320, rs4878628, rs10758321, and rs10758322 of a CREB3 subtype gene; rs4722778, rs177479, rs177480, rs11981754, rs177486, rs177498, rs2175738, rs17156579, rs17156603, rs17642145, rs10229500, rs10243659, rs4722785, rs16874503, rs11772815, rs6958133, rs16874525, rs17715174, rs6953524, rs10239810, rs17156649, rs1811248, rs887623, rs740988, rs7794304, rs6952227, rs42695, rs1029897, rs4722793, rs10233653, rs6955105, rs17156685, rs17156694, rs17156699, rs177572, rs177573, rs177574, rs177576, rs13437706, rs177580, rs177581, rs12666636, rs177584, rs177585, rs216715, rs10951197, rs160335, rs1008262, rs310353, rs310359, rs41273, rs1637457, rs17156919, rs41276, rs160375, rs917275, rs41348, rs886816, rs17157048, rs6462098, rs10951201, rs13311248, rs12540480, rs10265166, rs7798774, rs7799246, rs6972081, rs12533079, rs7806547, rs6462100, rs6979352, rs6950574, rs4722835, rs2066979, rs10486591, rs721993, rs2237351, rs3735566, rs11975539, rs6462107, rs2190306, rs4719955, and rs10228137 of a CREB5 subtype gene; and rs1153711, rs1153702, rs7583431, rs1153699, rs2302663, rs3845744, rs212349, rs212347, rs12693057, rs1153685, rs212360, rs212361, rs2072538, rs1205399, rs1153676, rs7566401, rs7578569, rs3755490, rs13388308, rs11888507, rs10497434, rs268214, rs166531, rs268228, rs268229, rs268230, rs268231, rs10497435, rs1982235, rs268237, rs13030474, and rs268174 of an ATF2 subtype gene.
10 . The method according to claim 1 or 4 , wherein the haplotype is at least one selected from the following table.
TABLE 1
Gene name CREB1
Linkage disequilibrium block No.
1
Gene polymorphism name ()
1
2
3
12
13
17
Haplotype No.
Tag
Tag
Tag
4
5
6
7
8
9
10
11
Tag
Tag
14
15
16
Tag
H1
C
C
C
A
G
G
G
T
C
C
C
C
C
C
A
A
T
H2
C
C
A
G
A
T
A
C
T
A
T
C
C
T
G
G
T
H3
C
T
C
A
G
G
A
T
T
C
C
C
C
C
A
A
T
H4
T
C
A
G
A
T
A
C
T
A
T
C
A
T
G
G
C
H5
C
C
A
G
A
T
A
C
T
A
T
A
C
C
A
A
T
H6
T
C
A
G
A
T
A
C
T
A
T
C
C
T
G
G
T
H7
T
C
A
G
A
T
A
C
T
A
T
C
A
T
G
G
T
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
() 1~17: (in this order)rs16839837, rs2360969, rs10932200, rs2253206, rs2551640, rs11904814, rs16839883, rs6740584, rs3770704, rs2254137, rs2551645, rs2551946, rs4234080, rs2952768, rs2709386, rs7591784 and rs7594560
TABLE 2
Gene name CREB3
Linkage disequilibrium block No.
1
Gene polymorphism name ()
1
2
3
9
11
Haplotype No.
Tag
Tag
Tag
4
5
6
7
8
Tag
10
Tag
12
13
14
15
16
17
18
19
20
21
22
23
24
H1
G
C
G
T
A
T
T
T
C
T
C
C
G
C
T
G
T
G
T
C
A
G
G
A
H2
G
C
G
T
A
T
T
T
T
T
C
C
G
C
T
G
T
G
T
C
A
G
G
A
H3
T
T
A
T
A
T
C
T
C
T
T
C
G
A
G
A
C
A
C
C
G
T
G
C
H4
T
T
A
T
A
T
C
T
C
T
C
C
G
A
G
A
C
A
C
C
G
T
G
C
H5
T
C
G
C
C
C
C
C
C
T
C
C
A
A
G
G
C
A
T
C
A
T
A
C
H6
T
T
G
T
A
T
C
T
C
C
C
T
G
A
T
G
C
G
T
C
A
G
G
C
H7
T
C
A
T
A
T
C
T
C
T
T
C
G
A
G
A
C
A
G
C
G
T
G
C
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
Linkage disequilibrium block No.
2
Gene polymorphism name ()
25
26
29
36
38
39
Haplotype No.
Tag
Tag
27
28
Tag
30
31
32
33
34
35
Tag
37
Tag
Tag
40
H8
C
C
G
G
G
C
G
G
G
A
T
A
C
C
G
C
H9
C
T
A
T
G
T
A
G
A
G
A
A
T
C
A
T
H10
T
C
G
G
C
T
G
A
A
G
A
A
T
C
G
C
H11
C
T
A
G
G
T
A
G
A
G
A
A
T
C
G
T
H12
C
C
G
G
C
T
G
A
A
G
A
A
T
C
G
C
H13
C
T
A
T
G
T
A
G
A
G
A
G
T
C
A
T
H14
C
C
G
G
G
C
G
G
G
A
T
A
C
T
G
C
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
() 1~40: (in this order)rs1243872, rs2145925, rs2025126, rs1885373, rs1885374, GA007473, rs2295794, rs4879926, GA007477, rs867194, rs11541908, rs741917, rs7862485, rs2756894, rs2249250, rs2295795, rs877365, rs2737273, rs2295797, rs2295798, rs1534847, rs7873822, rs2737274, rs10972567, rs3763630, rs10814274, rs3750434, rs1570246, GA025684, rs1570248, rs1570249, rs34478611, rs1322045, rs1951432, GA025687, rs10814275, rs10758320, rs4878628, rs10758321 and rs10758322
TABLE 3
Gene name crEB5
Linkage disequilibrium block No.
1
5
6
9
10
Gene polymorphism name ()
1
2
5
6
7
8
9
11
13
14
15
16
17
18
Haplotype (H) No.
Tag
Tag
3
4
Tag
Tag
H No.
Tag
Tag
Tag
10
Tag
12
H No.
Tag
Tag
H No.
Tag
Tag
H No.
Tag
Tag
H1
C
T
A
A
G
C
H6
C
C
G
C
A
G
H11
T
G
H14
T
A
H17
G
T
H2
G
C
G
A
G
T
H7
C
A
A
C
G
G
H12
C
C
H15
C
A
H18
G
G
H3
G
C
G
A
A
T
H8
C
C
G
C
G
G
H13
C
G
H16
C
G
H19
A
G
H4
C
C
G
A
G
T
H9
T
A
A
C
G
A
. . .
. . .
. . .
H5
G
C
G
A
G
C
H10
C
C
A
C
G
G
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
Linkage disequilibrium block No.
11
12
13
15
16
Gene polymorphism name ()
19
20
21
22
23
24
25
26
27
28
29
30
31
Haplotype (H) No.
Tag
Tag
H No.
Tag
Tag
Tag
H No.
Tag
Tag
H No.
Tag
Tag
Tag
H No.
Tag
Tag
Tag
32
33
H20
T
A
H24
G
C
C
H28
A
A
H31
G
T
C
H35
C
C
C
G
C
H21
T
G
H25
G
C
T
H29
G
A
H32
A
C
T
H36
T
C
A
G
C
H22
C
G
H26
A
C
T
H30
G
G
H33
A
T
T
H37
C
C
A
G
C
H23
C
A
H27
G
T
T
. . .
H34
A
T
C
H38
T
T
C
A
T
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
Linkage disequilibrium block No.
25
26
27
32
Gene polymorphism name ()
34
35
36
37
38
39
40
42
43
44
45
47
50
Haplotype (H) No.
Tag
Tag
H No.
Tag
Tag
Tag
Tag
H No.
Tag
41
H No.
Tag
Tag
Tag
Tag
46
Tag
48
49
Tag
H39
T
A
H42
G
A
G
G
H47
A
A
H49
A
T
C
G
T
G
T
T
T
H40
C
G
H43
G
A
A
A
H48
G
G
H50
A
T
C
G
T
G
T
T
C
H41
T
G
H44
A
G
G
A
. . .
H51
A
T
A
C
C
G
T
C
C
. . .
H45
G
A
G
A
H52
C
T
A
C
T
T
C
T
C
H46
G
G
G
A
H53
C
T
A
C
T
G
C
T
C
. . .
H54
A
C
C
G
T
G
T
T
T
H55
A
T
A
G
T
G
T
T
C
Haplotypes which are estimated to occur at a frequency of less than 1%
Linkage disequilibrium block No.
33
35
40
Gene polymorphism name ()
51
52
53
54
57
58
59
Haplotype (H) No.
Tag
Tag
Tag
Tag
55
56
H No.
Tag
Tag
H No.
Tag
60
61
62
63
64
H56
T
G
G
C
A
A
H61
C
T
H64
G
G
C
T
T
C
H57
T
A
A
T
G
C
H62
T
C
H65
A
A
T
C
C
A
H58
G
A
A
C
G
C
H63
T
T
. . .
H59
T
A
G
C
A
A
. . .
H60
T
A
A
C
G
C
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
() 1~64: (in this order)rs4722778, rs177479, rs177480, rs11981754, rs177486, rs177498, rs10229500, rs10243659, rs4722785, rs16874503, rs11772815, rs6958133, rs16874525, rs17715174, rs6953524, rs10239810, rs17156649, rs1811248, rs887623, rs740988, rs6952227, rs42695, rs1029897, rs10233653, rs6955105, rs17156699, rs177572, rs177573, rs177580, rs177581, rs12666636, rs177584, rs177585, rs1008262, rs310353, rs41273, rs1637457, rs17156919, rs41276, rs160375, rs917275, rs17157048, rs6462098, rs10951201, rs13311248, rs12540480, rs10265166, rs7798774, rs7799246, rs6972081, rs12533079, rs7806547, rs6462100, rs6979352, rs6950574, rs4722835, rs721993, rs2237351, rs3735566, rs11975539, rs6462107, rs2190306, rs4719955 and rs10228137
TABLE 4
Gene name ATF2
Linkage disequilibrium block No.
1
2
Gene polymorphism name ()
1
2
3
4
5
Haplotype No.
Tag
Tag
Tag
Tag
Tag
6
7
8
9
10
11
12
13
14
15
16
H1
T
C
A
A
G
C
C
A
G
C
G
T
C
A
A
A
H2
G
C
A
G
G
T
T
G
A
T
A
C
A
C
C
G
H3
T
T
C
G
A
T
T
G
A
T
A
C
A
C
C
G
H4
T
T
A
G
A
T
T
G
A
T
A
C
A
C
C
G
G
G
T
T
G
A
T
A
C
A
C
C
G
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
Linkage disequilibrium block No.
2
Gene polymorphism name ()
21
28
Haplotype No.
17
18
19
20
Tag
22
23
24
25
26
27
Tag
29
30
31
H5
C
T
T
C
C
C
G
A
C
A
C
T
T
G
T
H6
T
C
C
T
T
T
A
G
A
C
T
G
C
G
C
H7
T
C
C
T
T
T
A
G
A
C
T
T
C
G
C
H8
T
C
C
T
T
T
A
G
A
C
T
G
C
G
C
H9
T
C
C
T
C
C
G
A
C
A
C
T
T
G
T
. . .
Haplotypes which are estimated to occur at a frequency of less than 1%
() 1~31: (in this order)rs1153711, rs1153702, rs7583431, rs2302663, rs3845744, s212349, rs212347, rs12693057, rs1153685, rs212360, rs212361, rs2072538, rs1205399, rs1153676, rs7566401, rs7578569, rs3755490, rs13388308, rs11888507, rs10497434, rs268214, rs166531, rs268228, rs268229, rs268230, rs268231, rs10497435, rs1982235, rs268237, rs13030474 and rs268174
11 . A method for determining the type, amount, and/or frequency of administration of a drug to be administered to an individual, comprising using the result from the evaluation by the method according to claim 1 or 4 as an index.
12 . A method for predicting a side effect of a drug to be administered to an individual, comprising using the result from the evaluation by the method according to claim 1 or 4 as an index.
13 . The method according to claim 1 or 7 , wherein the drug is an opioid receptor function modulator and/or a cyclic AMP responsive element binding protein function modulator.
14 . The method according to claim 13 , wherein the opioid receptor function modulator is at least one selected from the group consisting of methamphetamine, methylenedioxymethamphetamine, amphetamine, dextroamphetamine, dopamine, morphine, DAMGO, codeine, methadone, carfentanil, fentanyl, heroin, cocaine, naloxone, naltrexone, nalorphine, levallorphan, pentazocine, pethidine, buprenorphine, oxycodone, hydrocodone, levorphanol, etorphine, dihydroetorphine, hydromorphone, oxymorphone, tramadol, diclofenac, indomethacin, flurbiprofen axetil, marcaine, ethanol, methanol, diethyl ether, propanol, butanol, flupirtine, laughing gas, F3 (1-chloro-1,2,2-trifluorocyclobutane), halothane, estradiol, dithiothreitol, thioridazine, pimozide, fluoxetine, paroxetine, desipramine, imipramine, clomipramine, tetramide, isoflurane, ginsenoside, ifenprodil, bupivacaine, tertiapin, clozapine, haloperidol, SCH23390, and cocaine; and the cyclic AMP responsive element binding protein function modulator is at least one selected from the group consisting of phosphodiesterase 4 (PDE4), calcineurin, protein kinase A, protein kinase C, p90 ribosome S6 kinase 1 (RSK1), calmodulin kinase, glycogen synthase kinase 3β, and CREB-regulated transcription coactivator 1 (CRTC1).
15 . The method according to claim 1 or 4 , comprising using an oligonucleotide consisting of a nucleotide sequence of at least 10 nucleotides comprising the 51 st nucleotide of the nucleotide sequence represented by any one of SEQ ID NOS: 1 to 172, or a complementary nucleotide sequence thereto, which can specifically hybridize to a DNA fragment comprising a gene polymorphism of a cyclic AMP responsive element binding protein gene.
16 . The method according to claim 15 , wherein the oligonucleotide spans a length of 10 to 150 nucleotides.
17 . The method according to claim 15 , wherein the oligonucleotide is selected from the group consisting of the nucleotide sequence represented by any one of SEQ ID NOS: 1 to 172 and a complementary nucleotide sequence thereto.
18 . A gene polymorphism marker for evaluating a tendency in the presence or absence of an individual drug sensitivity, comprising a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism.
19 . A gene polymorphism marker for evaluating a tendency in the presence or absence of an individual disease vulnerability, comprising a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism.Join the waitlist — get patent alerts
Track US2017357750A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.